The CFO as the enterprise decision engine: Why pharma finance functions are being rebuilt and what the next 24 months demand

Pharma CFOs are navigating an increasingly complex business environment. From portfolio investments and pricing pressure to manufacturing strategy and AI adoption, the pace and stakes of decision-making continue to rise. The organizations pulling ahead are the ones that rely on finance as an enterprise decision engine—using data, insight, and judgment to help the business allocate capital more effectively, respond faster to change, and create long-term value.

Across our work with pharma CFOs, one observation keeps recurring: the mandate of the finance function has expanded faster than its operating model.

Capital decisions that once moved on annual cycles now move continuously. Margin protection has shifted from an accounting estimate into a strategic lever. Manufacturing strategy—once primarily an operational concern—now lands on the CFO’s desk before it lands on operations. As a result, finance is increasingly expected to help shape the business’s most important decisions, not simply report the outcomes.

For many organizations, the challenge is that the finance function was never designed for this role.

In practice, finance leaders are now expected to answer questions they did not traditionally own. Which clinical assets deserve continued R&D investment? How should the manufacturing network evolve under changing trade realities? Which launches warrant incremental commercial investment? Where are pricing changes eroding margin faster than the organization can model them? Which acquisitions will create scalable value rather than operational complexity?

These are now core finance questions—and they require capabilities that many operating models were not built to support.

Four forces are reshaping the CFO mandate

Several structural shifts are changing both the volume of decisions finance must support and the consequences of getting those decisions wrong.

• Capital allocation has become continuous. Loss of exclusivity, pipeline investments, and the rising cost of late-stage clinical development have turned annual budgeting into an ongoing series of portfolio decisions. Finance is expected to underwrite those choices with greater speed and precision.
• Margin management has become more dynamic. Pricing pressure, reimbursement changes, and evolving payer dynamics have transformed gross-to-net management from a quarterly exercise into a strategic capability requiring far greater visibility.
• Manufacturing has become a financial decision. Supply chain resilience, reshoring, capacity investments, and geopolitical uncertainty all carry significant financial implications that increasingly require finance leadership.
• Data has become the limiting factor. Fragmented systems, inconsistent master data, and disconnected processes often slow forecasting, scenario planning, and AI adoption. In many organizations, the biggest barrier to scaling AI is not the technology itself—it’s the underlying data foundation.

AI changes what finance can do

For years, finance organizations focused on efficiency through standardization, outsourcing, and automation. Those improvements delivered significant value, but many of the traditional cost-reduction opportunities have now been realized.

AI introduces a different opportunity

Rather than simply reducing effort, AI creates capacity that finance can redirect toward higher-value work. As more routine processes become automated, finance professionals can spend more time supporting capital allocation, portfolio strategy, forecasting, and business partnering.

The technology matters, but operating model decisions matter even more. Organizations that see the greatest impact are not simply deploying AI. They are redesigning finance around faster decisions, stronger data, and closer partnership with the business.

The next 24 months represent an important window for pharma CFOs. Those that strengthen their data foundation, modernize their operating model, and embed finance more deeply into strategic decisions will be better positioned to improve growth, protect margins, and allocate capital more effectively.

Read the full article to explore the four operating-model moves that are helping leading pharma finance organizations accelerate decision-making and create enterprise value.